CompletedObservationalLast updated Oct 4, 2024

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Overview

ClinicalTrials.gov ID: NCT03061955
Lead Sponsor: Wake Forest University Health SciencesOTHER
Brief Summary: The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.

Status

Overall Status: Completed
Start Date: Oct 1, 2016Actual
Primary Completion Date: Mar 31, 2017Actual
Completion Date: Apr 26, 2019Actual

Study Record Dates

First Submitted: Feb 9, 2017
First Submitted that Met QC Criteria: Feb 20, 2017
First Posted: Feb 23, 2017Actual
Last Update Submitted that Met QC Criteria: Oct 2, 2024
Last Update Posted: Oct 4, 2024Actual
Last Verified: Jul 2019

NCT04355806Unknown status

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

NCT02124161Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT03590808Completed

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

NCT03315975Active, not recruiting

Flu Vaccine Responses in the Setting of Melanoma Treatment

NCT04526574Completed

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT05027932Completed

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine